Results 11 to 20 of about 61,737 (200)

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

PLoS Neglected Tropical Diseases, 2022
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable.
Alex P Salam, Alexandre Duvignaud, Marie Jaspard, Denis Malvy, Miles Carroll, Joel Tarning, Piero L Olliaro, Peter W Horby   +7 more
doaj   +2 more sources

Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis

International Journal of Infectious Diseases, 2019
Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this ...
Kirsten Alexandra Eberhardt, Johannes Mischlinger, Sabine Jordan, Mirjam Groger, Stephan Günther, Michael Ramharter   +5 more
doaj   +2 more sources

Ribavirin Induces Polyamine Depletion via Nucleotide Depletion to Limit Virus Replication

Cell Reports, 2019
Summary: Common antivirals include nucleoside or nucleotide analogs with base prodrugs. The antiviral ribavirin, a US Food and Drug Administration (FDA)-approved nucleoside antimetabolite, halts guanine production, mutagenizes viral genomes, and ...
Patrick M. Tate, Vincent Mastrodomenico, Bryan C. Mounce   +2 more
doaj   +2 more sources

Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan.
Shah S, Mafirakureva N, Trickey A, Hasnain A, Khan U, Khowaja S, Ashraf H, Baig-Ansari N, Hickman M, Vickerman P, Walker JG, Lim AG.   +11 more
europepmc   +2 more sources

Ribavirin treatment for respiratory syncytial virus infection in patients with hematologic malignancy and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.

Clinical Microbiology and Infection, 2023
BACKGROUND Ribavirin use for respiratory syncytial virus (RSV) infection in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT) recipients remains controversial.
Kasama Manothummetha, Thanuthong Mongkolkaew, P. Tovichayathamrong, Rabhas Boonyawairote, Tanaporn Meejun, Karan Srisurapanont, Kasidis Phongkhun, A. Sanguankeo, P. Torvorapanit, Chatphatai Moonla, R. Plongla, Olivia S. Kates, R. Avery, Saman Nematollahi, N. Permpalung   +14 more
semanticscholar   +1 more source

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19

Journal of Medical Virology, 2020
Confronting the challenge of the outbreak of COVID‐19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of ...
Jahan S Khalili, Haizhen Zhu, A. Mak, Yongqi Yan, Yi Zhu   +4 more
semanticscholar   +1 more source

Ribavirin therapy for severe COVID-19: a retrospective cohort study

International Journal of Antimicrobial Agents, 2020
Highlights • Patients in the experimental group received intravenous ribavirin versus supportive care only in the control group.• Ribavirin was not associated with reduced negative conversion time of SARS-CoV-2 PCR test compared with the control group ...
Song Tong, Yuan Su, Yuan Yu, Chuangyan Wu, Jiuling Chen, Sihua Wang, Jinjun Jiang   +6 more
semanticscholar   +1 more source

Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis

Annals of Hepatology, 2007
The aim of this study was to investigate the effects of combinations of pegilated–interferon (PEG–IFN), ribavirin, and danazol on thrombocytopenia and liver injury in rats with fibrosis.
Guillermo Cabrera Álvarez, Vicente Madrid-Marina, Ricardo Jimenez-Mendez, Angel Leon Buitimea, Margarita Bahena Román, Rudyard Cortez-Gomez, Jorge Reyes Esparza, Lourdes Rodríguez-Fragoso   +7 more
doaj   +1 more source

Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. [PDF]

PLoS ONE, 2011
The nucleoside analogue Ribavirin significantly increases patient response to IFN-α treatment of HCV, by directly inhibiting viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific
Nigel J Stevenson, Alison G Murphy, Nollaig M Bourke, Catherine A Keogh, John E Hegarty, Cliona O'Farrelly   +5 more
doaj   +1 more source

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Journal of Antimicrobial Chemotherapy, 2020
Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2.
G. Eslami, S. Mousaviasl, E. Radmanesh, Saeed Jelvay, Saeid Bitaraf, Bryony Simmons, H. Wentzel, A. Hill, A. Sadeghi, J. Freeman, S. Salmanzadeh, Hani Esmaeilian, M. Mobarak, R. Tabibi, Amir Hosein Jafari Kashi, Z. Lotfi, Seyed Mehdi Talebzadeh, Aseni Wickramatillake, M. Momtazan, M. Hajizadeh farsani, S. Marjani, S. Mobarak   +21 more
semanticscholar   +1 more source